JAX-NYSCF and GSK Unite for 5-Year Neurodegenerative Models Push

The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) announces a five-year strategic research partnership with GSK to develop advanced human cellular models for neurodegenerative diseases, including Alzheimer’s disease.

Bridging Discovery and Therapy Development

This initiative combines human stem cell research, cutting-edge data science, and large-scale systems to address gaps between scientific findings and new treatments. Researchers aim to create disease-specific cellular models that reveal the biology of conditions like Alzheimer’s and speed up insights into potential therapies.

“This collaboration highlights the future of early biomedical research,” states Lon Cardon, president and CEO of JAX, which recently expanded through the acquisition of NYSCF. “It allows us to extend discoveries and hasten therapies for patients by linking traditional models with scalable patient-derived induced pluripotent stem cell (iPSC) models that better reflect human biology.”

Integrating Expertise for Better Predictions

GSK contributes its expertise in neurodegeneration, translational science, and drug discovery, while JAX-NYSCF provides stem cell technology, patient data access, and automation tools. Together, they seek to develop superior predictive models to identify and prioritize drug candidates.

“This partnership enhances GSK’s cellular disease modeling efforts and could unlock new insights to accelerate therapies for neurodegenerative conditions,” says Chris Austin, senior vice president and global head of Research Technologies at GSK. “It enables more accurate models, better medicines, and identification of patients likely to benefit.”